Treatment with camrelizumab plus tyrosine kinase inhibitors with or without TACE for intermediate-advanced hepatocellular carcinoma: a clinical efficacy and safety study
暂无分享,去创建一个
Jingdong Li | Yongfu Xiong | Yongheng Li | Kun He | Chunliu Meng | Yi He | Y. Xian | Y. Yin
[1] Lu Zheng,et al. Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis , 2021, Frontiers in Oncology.
[2] Xinwei Han,et al. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients , 2021, Frontiers in Pharmacology.
[3] Wendong Li,et al. Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib , 2021, OncoTargets and therapy.
[4] W. Fang,et al. A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression , 2021, Liver Cancer.
[5] S. Su,et al. Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis , 2021, Frontiers in Oncology.
[6] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[7] W. Huang,et al. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study , 2020, OncoTargets and therapy.
[8] Y. Chang,et al. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma , 2020, International journal of molecular sciences.
[9] Ju Dong Yang,et al. New advances in the diagnosis and management of hepatocellular carcinoma , 2020, BMJ.
[10] Jianming Xu,et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.
[11] P. Thuluvath,et al. A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma , 2020, Annals of translational medicine.
[12] Yue Hu,et al. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial , 2020, Frontiers in Oncology.
[13] Xiuhua Lu,et al. The clinical application of camrelizumab on advanced hepatocellular carcinoma , 2020, Expert review of gastroenterology & hepatology.
[14] Li Zhang,et al. Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients , 2020, Thoracic cancer.
[15] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[16] W. Fang,et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial , 2020, Journal of Hematology & Oncology.
[17] W. Fang,et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. , 2020, The Lancet. Oncology.
[18] R. Motzer,et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Shriti Singh,et al. Challenges in liver cancer and possible treatment approaches. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[20] S. Keam,et al. Camrelizumab: First Global Approval , 2019, Drugs.
[21] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[22] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[23] J. Bruix,et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. , 2018, Journal of hepatology.
[24] Gisela Schwab,et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.
[25] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[26] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[27] Deborah A. Bowen,et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. , 2017, Blood.
[28] Jeffrey A. Engelman,et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.
[29] F. Stossi,et al. Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming , 2017, Nature.
[30] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[31] M. Plummer,et al. World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.
[32] Lequn Li,et al. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma , 2014, Annals of surgery.
[33] S. Fan,et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. , 2014, Gastroenterology.
[34] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[35] Shelly C. Lu. Where are we in the chemoprevention of hepatocellular carcinoma? , 2009, Hepatology.
[36] S. Caldwell,et al. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology , 2009, Journal of Gastroenterology.
[37] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[38] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[39] Matthew S. Johnson,et al. The diagnosis and treatment of hepatocellular carcinoma. , 1998, Seminars in diagnostic pathology.
[40] E. Buchbinder,et al. CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.
[41] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.